Hims & Hers Health Enters Low Testosterone Treatment Market

Hims & Hers Health is launching testosterone treatments on its telehealth platform, offering oral testosterone Kyzatrex and injectable treatments starting next year. The company will also allow providers to prescribe compounded enclomiphene, which aims to restore testosterone production without compromising fertility. This expansion into low testosterone treatments marks Hims & Hers Health's further venture into a category often marred by stigma, according to its CEO.

Hims & Hers Health, a telehealth company specializing in men's health, is set to launch testosterone treatments on its platform. The company will offer oral testosterone Kyzatrex and injectable treatments starting in the next year. Additionally, it will allow providers to prescribe compounded enclomiphene, an off-label therapy aimed at restoring testosterone production without compromising fertility Hims & Hers To Launch Low Testosterone Treatments for ...^[1].

The move comes as the company continues to expand its offerings in the hormonal health segment. CEO Andrew Dudum has indicated that the company aims to address hormonal health issues affecting more than 50 million Americans, which have long been overlooked by traditional care Enclomiphene and Weight Loss: How It Affects Body ...^[2]. This expansion is a strategic move for Hims & Hers Health, which has been experiencing a slowdown in weight-loss drug sales and is looking to diversify its revenue streams Hims & Hers To Launch Low Testosterone Treatments for ...^[1].

The initial rollout of these treatments will target men, but the company has stated its intention to add hormonal therapies for women in perimenopause and menopause in the future. The company recently expanded into diagnostics with the acquisition of an at-home lab testing firm, enabling easier testosterone testing and offering lab services as a standalone product Hims & Hers To Launch Low Testosterone Treatments for ...^[1].

Hims & Hers Health's stock has nearly doubled so far in 2025, reflecting investor optimism amid the company's strategic expansion into the testosterone treatment market. Retail sentiment on Stocktwits has been bullish, with normal message volume Hims & Hers To Launch Low Testosterone Treatments for ...^[1].

Enclomiphene, the compounded therapy, is a selective estrogen receptor modulator (SERM) that works by increasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH), boosting the body's natural testosterone production. Unlike testosterone replacement therapy (TRT), enclomiphene stimulates the hypothalamic-pituitary-gonadal (HPG) axis, helping the body restore its own hormone levels Enclomiphene and Weight Loss: How It Affects Body ...^[2].

While enclomiphene is not a weight loss drug, it can support gradual improvements in body composition by increasing muscle mass and reducing fat stores. It is crucial to combine enclomiphene with a balanced diet and regular exercise for optimal results Enclomiphene and Weight Loss: How It Affects Body ...^[2].

The company's expansion into testosterone treatments is a significant step, positioning Hims & Hers Health as a leader in the growing hormonal health segment. This move is expected to attract more investors and further boost the company's stock performance.